12 weeks (avg 6 mg/week) 8 vials 72 mg total needed
The GLP-1 RA exenatide was included in Table 3 despite lacking an indication for weight loss, given the evidence presented by Mitchell et al
2T2DM-1GLP-1GLP-1RGLP-1R GLP-1GLP-1GLP-1+GLP-1GLP-1GLP-1 2023128GLP-13GLP-1NMPA/FDA1GLP-1FDANMPATGA7GLP-1 01GLP-1 GLP-11983 , L GLP-1GLP-17-36GLP-17-37, 30GLP-17-36GLP-17-37 GLP-1GLP-1RGLP-1GLP-1 GLP-1 GLP-1[1] GLP-14dipeptidyl dipeptidase-4DPP-4GLP-1RGLP-1DPP-4 GLP-1 GLP-1 DPP-4 MetforminSimvastatin GLP-1RDPP-4 GLP-1 GLP-1RDPP-4 GLP-1RDPP-4 GLP-1RDPP-4GLP-1RGLP-1 1-2 DPP-4 GLP-1RDPP-4[1] GLP-1R 2 GLP-1RGLP-1R GCGRGLP-2RGIPR GHRHRB1GPCR GLP-1RGGsGiGoGq/11GLP-1GLP-1RGsACcAMPcAMPAPKAcAMP2Epac2 PKA ATP K+ PKA Ca2+VDCC Ca2+ Epac2 Ras 1Rap1 CPLC IP3 DAG Ca2+ GLP-1R [2] 02 GLP-1 80%PEGFc / ExenatideFDA1GLP-1R392Amylin -PLGA1Bydureon20112012FDA GLP-1DOEGLP-1 03 GLP-1 GLP-1AAALACGLP-like / : GLP-1 GLP-1Cetagliptin50mg24DPP-480%GLP-1Cetagliptin D-GLP-1 [3] 04 GLP-1 GLP-1/PK PK Compound A 0.020.050.1 mg/kg CompoundACmax 1:2.8:6.5AUC(0-t)1:2.8:5.7Cmax AUC(0-t)0.02 mg/kg Compound A0.02 mg/kg 82.9% 05 GLP-1 2022930CDEOzempic-1GLP-1/221GLP-1 Ozempic GLP-1 2022829GLP-1105 I GLP-1GLP-1R CDE202320244-5 MDR-001 2023420CDEMDR-0012MDR-001AIMolecule ProGLP-1R202212FDAMDR-001ADMEbest-in-class MDR-001ADMEMDR-001HbA1C MDR-001GLP-1R 06 GLP-1RGLP-1R CRO20INDANDANMPAINDUS FDAIND/ANDANMPAIND/ANDA [1] Baptist Gallwitz
Febuxostat is a non-purine analog that functions as a selective non-competitive inhibitor of the active site of xanthine oxidase
Alimentacin por sonda: administrar 10 g de glutamina al da, infundir la mezcla con una jeringa por sonda de alimentacin
Gastroparesis (Severely Delayed Stomach Emptying) / Bowel Obstruction: Persistent and severe nausea, vomiting, or abdominal pain should be reported
